{"schema_version":"1","generated_at":"2026-10-31T23:45:38.767Z","data_as_of":null,"url":"https://www.findmykol.com/kol/vijay-kasturi","json_url":"https://www.findmykol.com/kol/vijay-kasturi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"vijay-kasturi","name":"Vijay Kasturi","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"AVEO Oncology","institution_url":"https://www.findmykol.com/institution/aveo-oncology","city":"Worcester","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1821071077","openalex":"A5015358832"},"summary":"Vijay Kasturi is an Oncology physician affiliated with AVEO Oncology. OpenAlex indexes 58 publications with 535 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":58,"cited_by_count":535,"h_index":10,"latest_activity_year":2024,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06567743","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"CG Oncology, Inc.","source_url":"https://clinicaltrials.gov/study/NCT06567743","trial_url":"https://www.findmykol.com/trial/NCT06567743"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"EMD Serono, Inc.","program_year":2021,"amount_usd":5759.51,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821071077"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1821071077","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial","year":2024,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyad348","status":"verified"},{"title":"Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients","year":2024,"journal":"BMC Health Services Research","source_url":"https://doi.org/10.1186/s12913-024-11587-8","status":"verified"},{"title":"Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial","year":2023,"journal":"The Oncologist","source_url":"https://doi.org/10.1093/oncolo/oyad132","status":"verified"},{"title":"Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2023.41.4_suppl.585","status":"verified"},{"title":"673 FIERCE-HN: a multicenter, randomized, placebo-controlled, phase 3 study of ficlatuzumab + cetuximab in pts w/recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC)","year":2023,"journal":"Regular and Young Investigator Award Abstracts","source_url":"https://doi.org/10.1136/jitc-2023-sitc2023.0673","status":"verified"}],"source":"works"},"contact":{"address_1":"33 KENDALL STREET","address_2":"UMASS MEMORIAL CAMPUS","city":"Worcester","state":"MA","zip":"01605","phone":"508-334-6276","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1821071077","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2010-12-10","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}